Citius Oncology Financials - Benzinga

Citius Oncology Inc

CTORNASDAQ

Trade with Public

Trade with Public

$0.8101

마지막 업데이트: Aug 25, 4:00 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 비교 주식 보고서

Citius Oncology Financials

Citius Oncology (CTOR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate

Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494

Benzinga Newsdesk

Earnings Breakdown: Citius Oncology Q1

Benzinga Insights

Citius Oncology Q1 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Citius Oncology Q1 EPS $(0.06) Misses $(0.04) Estimate, Sales $3.944M Miss $4.373M Estimate

Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.09) per share from

Benzinga Newsdesk

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.

Mohd Haider

PRO
Citius Oncology Q4 EPS $(0.06), Inline

Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 57.14 percent increase over losses of $(0.14) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved